Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model

Overview of attention for article published in Frontiers in Pharmacology, August 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 38 X posts from 34 X users, with an upper bound of 274,458 followers.

RT @MAugusterfer: PBM Profits! think about how much money PATIENTS would have saved...

RT @paras_biotech: Marc Cuban Cost Plus Drug Company (MCCPDC) saving assessment (~$1.3B) on generic cardiology drugs (16 of 50 drugs) on 20…

PBM Profits! think about how much money PATIENTS would have saved...

RT @PearlF: Report says Medicare could have saved $1.3B or more on generic cardiology drugs in '22 if they bought the drugs through @costpl…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 34 additional X posts.